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Abstract
Background: Increasing multidrug resistance in gram-negative bacilli (GNB) infections poses a serious threat to
public health. Few studies have analyzed co-resistance rates, defined as an antimicrobial susceptibility profile in a
subset already resistant to one specific antibiotic. The epidemiologic and clinical utility of determining co-resistance
rates are analyzed and discussed.
Methods: A 10-year retrospective study from 2002–2011 of bloodstream infections with GNB were analyzed from
three hospitals in Greater Vancouver, BC, Canada. Descriptive statistics were calculated for antimicrobial resistance
and co-resistance. Statistical analysis further described temporal trends of antimicrobial resistance, correlations of
resistance between combinations of antimicrobials, and temporal trends in co-resistance patterns.
Results: The total number of unique blood stream isolates of GNB was 3280. Increasing resistance to individual
antimicrobials was observed for E. coli, K. pneumoniae, K. oxytoca, E. cloacae, and P. aeruginosa. Ciprofloxacin
resistance in E. coli peaked in 2006 at 40% and subsequently stabilized at 29% in 2011, corresponding to decreasing
ciprofloxacin usage after 2007, as assessed by defined daily dose utilization data. High co-resistance rates were
observed for ceftriaxone-resistant E. coli with ciprofloxacin (73%), ceftriaxone-resistant K. pneumoniae with
trimethoprim-sulfamethoxazole (83%), ciprofloxacin-resistant E. cloacae with ticarcillin-clavulanate (91%), and
piperacillin-tazobactam-resistant P. aeruginosa with ceftazidime (83%).
Conclusions: Increasing antimicrobial resistance was demonstrated over the study period, which may partially be
associated with antimicrobial consumption. The study of co-resistance rates in multidrug resistant GNB provides
insight into the epidemiology of resistance acquisition, and may be used as a clinical tool to aid prescribing empiric
antimicrobial therapy.
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Background
Gram-negative bacilli (GNB) are a significant cause of in-
fection in community and nosocomial settings [1]. Besides
inherent and chromosomally mediated mechanisms of re-
sistance, the development of multidrug resistance in
GNB is further facilitated by the acquisition of plasmids,
integrons and transposons carrying resistance genes, which
is typically a consequence of selective antimicrobial pres-
sure exerted by prolonged antibiotic use [2]. It is also
becoming increasingly common to find multiple re-
sistance genes that are linked together, thus antibiotics
from unrelated classes may contribute to the selective
pressures and maintain the expression of these multidrug
resistant genes [3,4].
The Infectious Diseases Society of America views anti-
microbial resistance as a serious threat to public health,
patient safety and national security, and has published
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policy recommendations for the US Congress to address
the rising rates of antibiotic resistance together with de-
clining approvals of new antibiotics [5]. Pop-Vicas and
D’Agata (2005) have emphasized the need to further ex-
pand our understanding of the dynamics of transmis-
sion of these multidrug resistant pathogens to determine
whether it is related to cross transmission from humans
to humans or antimicrobial selective pressures [6]. Kallen
and Srinivasan (2010) have also highlighted the import-
ance for ongoing surveillance of the incidence and epi-
demiology of multidrug resistant GNB [1].
Several studies have shown an increasing incidence of
multidrug resistant GNB [7-9]. However, to our know-
ledge, few studies provide a comprehensive evaluation of
co-resistance patterns with antimicrobial agents com-
monly used to treat GNB. Co-resistance is defined in this
study as the antimicrobial susceptibility profile in a subset
of isolates already resistant to a specific antibiotic, and
provides a different means for monitoring multidrug re-
sistance and displaying observed trends, such as increasing
multidrug resistance in P. aeruginosa that are resistant to
ciprofloxacin [10-12]. The study of co-resistance can thus
be quite broad and not limited to isolates that are known to
harbour multidrug resistance, such as those with ESBLs.
From a clinical perspective, co-resistance should be taken
into consideration when prescribing empiric therapy for pa-
tients being treated for specific GNB where local antimicro-
bial resistance rates are significant, and in patients who
have been exposed to prior courses of antimicrobial agents.
The aim of our study is to examine the antimicrobial
co-resistance patterns of GNB bloodstream isolates over a
10-year time period in order to document changes in sus-
ceptibility patterns, and to identify any potential causes
when significant changes occur. The utility of the informa-
tion gathered would be applicable in clinical practice when
tailoring empiric antibiotic treatment.
Methods
We conducted a 10-year retrospective study from Jan
2002 to Dec 2011 to quantify the trends of resistance and
co-resistance patterns in GNB isolated from bloodstream
infections at Vancouver Coastal Health (VCH), which in-
cludes Vancouver General Hospital (VGH) (a 950-bed ter-
tiary care teaching hospital with 21,000 admissions per
year), Richmond Hospital (a 175-bed community hospital),
and Lion's Gate Hospital (a 268-bed community hospital).
The study was approved by the University of British
Columbia Clinical Research Ethics Board and by the Van-
couver Coastal Health Research Institute.
Utilizing the VCH laboratory information system,
Sunquest®, which stores laboratory data in the Sunset® data-
base, a report was generated to identify all positive blood
cultures with GNB from 2002–2011. Further refinement
was performed through computer programming to include
only one bacterial isolate of the same identification (genus
and species) and susceptibility pattern per patient per cal-
endar year in the analysis. The first unique patient isolate
from the first admission during each study year was used
in cases where multiple isolates of the same genus, species
and susceptibility pattern were identified. When multiple
cultures taken from the same patient had the same GNB
identified but with any difference in susceptibility patterns,
these were considered unique isolates and were included
in the analysis. The Sunquest® system started to incorpor-
ate data for Richmond Hospital in April 2005 and Lion's
Gate Hospital in August 2007. Annual review of the anti-
microbial susceptibility patterns from the individual hospi-
tals in this study do not differ significantly from each other
and inclusion of additional sites over the study period was
not felt to influence results.
Identification and susceptibility testing were performed
using commercially available automated systems [BD
Phoenix™ (Sep 2009 to study end date) or Siemens Micro-
Scan® (2002 to Sept 2009) systems]. Quality control
measures were implemented during the changeover of
automated systems in 2009 for validation and verification to
ensure that the results on both systems were concordant
within acceptable limits. Antibiotic susceptibility testing was
performed and interpreted using guidelines and interpretive
breakpoints for susceptible, intermediate, and resistant
categories established by the Clinical and Laboratory Stan-
dards Institute (CLSI). All antimicrobial susceptibility results
that fell into the intermediate category were presumed to be
resistant for the purposes of this study. Guidelines for sus-
ceptibility breakpoints for cephalosporins were changed
after 2010, but the laboratory did not change to the new
guidelines since the panels for the commercial system in
use did not have concentration wells that were low enough
to allow interpretation at the lower breakpoints [13].
The data collected was extrapolated from Sunset® into a
Microsoft Access® database. Queries and reports of indi-
vidual antimicrobial resistance and co-resistance patterns
were generated to supply descriptive statistics for each
specific study year and pathogen. Pharmacy data on
inpatient antimicrobial consumption at VGH in the form
of defined daily doses (DDDs) were compared against
antimicrobial resistance results. Statistical analysis was
performed to determine linear-to-linear temporal trends
of individual antimicrobial resistance patterns. In addition,
Pearson correlation coefficients were determined for asso-
ciations between resistant combinations of antimicrobial
agents, and Pearson Chi-square test was performed to
assess for temporal trends in co-resistance patterns. P values
of ≤0.05 were used for statistical significance in all cases.
Results
The total number of unique blood stream isolates of
GNB was 3,280 over the 10-year study period, ranging
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annually from 109 (2002) to 463 (2010). The five most
common GNB isolated were Escherichia coli, Klebsiella
pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and
Pseudomonas aeruginosa, and the proportion of each is il-
lustrated in Figure 1. The temporal trends of resistance to
commonly used antibiotics for each of these organisms
are illustrated by line graphs in Figure 2.
For E. coli (Figure 2a), overall trends of increasing resist-
ance to cefazolin and ceftriaxone were observed over time.
Resistance to piperacillin-tazobactam remained stable at
4% from 2009 to 2011; it replaced ticarcillin-clavulanate
on the hospital formulary in 2009. Resistance to ciproflox-
acin and trimethroprim-sulfamethoxazole (TMP-SMX)
both peaked during 2006 at roughly 40% and stabilized at
lower levels of 29% and 34% respectively in 2011. Compar-
ing this with antimicrobial consumption data (Figure 3),
use of ciprofloxacin peaked in 2007 at 23,800 DDD and
decreased to 10,100 DDD in 2011, whereas TMP-SMX
consumption peaked in 2007 at 5,100 DDD, dropped to
4,200 DDD in 2009, and has increased back to 6,700 DDD
in 2011. A subgroup analysis of ESBL E. coli (total of 54
isolates in 2010 and 2011) revealed the following resist-
ance rates: ciprofloxacin (83%), piperacillin-tazobactam
(17%), TMP-SMX (76%), gentamicin (52%), ceftriaxone
(100%), and imipenem (0%). In contrast, non-ESBL E. coli
(total of 414 isolates in 2010 and 2011) had lower resist-
ance rates: ciprofloxacin (21%), piperacillin-tazobactam
(2%), TMP-SMX (26%), gentamicin (8%), ceftriaxone (3%),
and imipenem (0%).
For K. pneumoniae (Figure 2b), overall trends of increas-
ing resistance were observed with cefazolin, ceftriaxone
and piperacillin-tazobactam. Subgroup analysis for ESBL
K. pneumoniae (total of 12 isolates in 2010 and 2011) re-
vealed the following resistance rates: ciprofloxacin (50%),
piperacillin-tazobactam (42%), TMP-SMX (50%), gentami-
cin (42%), ceftriaxone (100%), and imipenem (0%). In con-
trast, non-ESBL K. pneumoniae (total of 118 isolates in
2010 and 2011) had lower resistance rates: ciprofloxacin
(10%), piperacillin-tazobactam (4%), TMP-SMX (8%), gen-
tamicin (2%), ceftriaxone (2%), and imipenem (1%).
For K. oxytoca (Figure 2c), increasing rates of resist-
ance to ceftriaxone, ciprofloxacin, TMP-SMX, and piperacillin-
tazobactam were observed. For E. cloacae (Figure 2d), re-
sistance rates increased with ceftriaxone, TMP-SMX, and
ciprofloxacin, but remained relatively stable with piperacillin-
tazobactam. For P. aeruginosa (Figure 2e), resistance rates
to ceftazidime, ciprofloxacin, and piperacillin-tazobactam
all increased. P. aeruginosa resistance to imipenem was
4.2% during 2007–2011 (from a baseline of 0% in 2002–
2006).
Chi-square trend tests were performed to determine
which temporal patterns of antimicrobial resistance fit
into a linear-by-linear association model. Linear-by-linear
trends were identified with cefazolin resistance in E. coli
(X2 = 9.062, p < 0.003), ceftriaxone resistance in E. coli (X2 =
13.070, p < 0.001), cefazolin resistance in K. pneumoniae
(X2 = 15.183, p < 0.001), ceftriaxone resistance in K.
pneumoniae (X2 = 18.066, p < 0.001), piperacillin-tazobactam
resistance in K. pneumoniae (X2 = 5.485, p < 0.019), and
cefazolin resistance in K. oxytoca (X2 = 4.329, p < 0.037).
Other temporal patterns that approached significance in a
linear-by-linear association model include ciprofloxacin
resistance in K. pneumoniae (X2 = 3.656, p = 0.056), TMP-
SMX resistance in K. oxytoca (X2 = 3.576, p = 0.059),
ticarcillin-clavulanate resistance in K. pneumoniae (X2 =
3.716, p = 0.054), and ceftazidime resistance in P. aerugi-
nosa (X2 = 3.213, p = 0.073). The temporal trend models
for E. coli resistant to ciprofloxacin and SMX-TMP are
curvilinear with calculated departure of linearity as a chi-
square for ciprofloxacin is 22.611 on 8df (p < 0.0039), and
for TMP-SMX is 15.31 on 8df (p = 0.053).
The second part of the analysis involved looking at
correlation patterns of resistance between various pairs
of antibiotics, which is commonly reported in other pub-
lications but does not provide information regarding co-
resistance as defined in this study. In E. coli (Table 1a),
high correlations of resistance were identified between
several combinations of antimicrobial agents including
piperacillin-tazobactam with ciprofloxacin (r = 0.973),
ticarcillin-clavulanate with cefazolin (r = 0.885), TMP-
SMX with ciprofloxacin (r = 0.871), ticarcillin-clavulanate
with TMP-SMX (r = 0.839), and ceftriaxone with cefazolin
(r = 0.808). In K. pneumoniae (Table 1b), highest correlations
of resistance were seen between piperacillin-tazobactam with
ceftriaxone (r = 0.982), ceftriaxone with cefazolin (r = 0.935),
Figure 1 Distribution of gram-negative bacilli isolated from
bloodstream isolates from 2002–2011. The total number of
unique bloodstream isolates during the study period was 3280.
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Figure 2 Temporal patterns of resistance to selected antimicrobial agents for a) E. coli, b) K. pneumoniae, c) K. oxytoca, d) E. cloacae,
and e) P. aeruginosa. Antimicrobial resistance rates were analyzed yearly for E. coli and K. pneumoniae, and combined into two time groups
of 2002–06 and 2007–11 for K. oxytoca, E. cloacae, and P. aeruginosa due to lower isolate numbers. Number of isolates for each GNB is listed
below the corresponding year or time groups. Y-axis represents resistance in percentage. Note: Pip-tazo is piperacillin-tazobactam,
TMP-SMX is trimethoprim-sulfamethoxazole, Tic-clav is ticarcillin-clavulanate.
Figure 3 Inpatient antimicrobial utilization at Vancouver General Hospital in defined daily dose (DDD) by calendar year. DDD is listed
on Y-axis. Note: Pip-tazo is piperacillin-tazobactam, TMP-SMX is trimethoprim-sulfamethoxazole, Tic-clav is ticarcillin-clavulanate.
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and ticarcillin-clavulanate with cefazolin (r = 0.893). In
K. oxytoca (Table 1c), highest correlations of resistance
were between ciprofloxacin with ceftriaxone (r = 0.952),
ticarcillin-clavulanate with ceftriaxone (r = 0.773), and
ticarcillin-clavulanate with ciprofloxacin (r = 0.773). In
E. cloacae (Table 1d), highest correlations of resistance
were observed between ticarcillin-clavulanate with ceftri-
axone (r = 0.944), piperacillin-tazobactam with ceftriaxone
(r = 0.927), and ticarcillin-clavulanate with TMP-SMX
(r = 0.781). Finally, in P. aeruginosa (Table 1e), resistance
Table 1 Pearson correlation matrixes showing Pearson correlation coefficients (r) of resistance between pairs of
antibiotics for a) E. coli, b) K. pneumonia, c) K. oxytoca, d) E. cloacae, e) P. aeruginosa
a) Pearson correlation matrix (r) for E. coli
Cefazolin Ceftriaxone Ciprofloxacin TMP-SMX Pip-tazo Tic-clav
Cefazolin (n = 1783)
Ceftriaxone (n = 1783) 0.808
Ciprofloxacin (n = 1783) 0.487 0.290
TMP-SMX (n = 1783) 0.770 0.503 0.871
Pip-tazo (n = 846) 0.702 0.623 0.973 0.865
Tic-clav (n = 1063) 0.885 0.299 0.733 0.839 nd
b) Pearson correlation matrix (r) for K. pneumoniae
Cefazolin Ceftriaxone Ciprofloxacin TMP-SMX Pip-tazo Tic-clav
Cefazolin (n = 480)
Ceftriaxone (n = 480) 0.935
Ciprofloxacin (n = 480) 0.630 0.566
TMP-SMX (n = 480) 0.719 0.689 0.274
Pip-tazo (n = 163) 0.917 0.982 0.886 0.778
Tic-clav (n = 295) 0.893 0.677 0.648 0.635 nd
c) Pearson correlation matrix (r) for K. oxytoca
Cefazolin Ceftriaxone Ciprofloxacin TMP-SMX Pip-tazo Tic-clav
Cefazolin (n = 127)
Ceftriaxone (n = 127) 0.576
Ciprofloxacin (n = 127) 0.619 0.952
TMP-SMX (n = 127) −0.598 −0.005 −0.184
Pip-tazo (n = 71) 0.011 −0.222 −0.349 −0.174
Tic-clav (n = 65) 0.649 0.773 0.773 0.013 nd
d) Pearson correlation matrix (r) for E. cloacae
Ceftriaxone Ciprofloxacin TMP-SMX Pip-tazo Tic-clav
Ceftriaxone (n = 170)
Ciprofloxacin (n = 170) 0.688
TMP-SMX (n = 170) 0.611 0.172
Pip-tazo (n = 83) 0.927 0.542 0.781
Tic-clav (n = 96) 0.944 0.613 0.781 nd
e) Pearson correlation matrix (r) for P. aeruginosa
Ceftazidime Ciprofloxacin Pip-tazo Tic-clav
Ceftazidime (n = 115)
Ciprofloxacin (n = 115) −0.457
Pip-tazo (n = 60) 0.177 0.225
Tic-clav (n = 65) 0.888 −0.100 nd
Number of isolates (n) included in each matrix is listed for each row. Pearson coefficients (r) which are bolded represent pairs with p values ≤ 0.05, while
those that are bolded and italicized trended towards significance with p values > 0.05 ≤ 0.07. Note: TMP-SMX is trimethoprim-sulfamethoxazole, Pip-tazo is
piperacillin-tazobactam, Tic-clav is ticarcillin-clavulanate; nd is not determined as isolates did not consistently have both Pip-tazo and Tic-clav
susceptibilities reported.
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to ticarcillin-clavulanate was highly correlated with ceftaz-
idime resistance (r = 0.888).
The final part of our analysis involved selecting out a
group of isolates that were resistant to one specific anti-
microbial agent and then examining that group's anti-
microbial susceptibility profile–the co-resistance pattern.
In E. coli (Table 2a), those that are resistant to ceftriax-
one have a 73% probability of also exhibiting resistance
to ciprofloxacin. In contrast, for those that are resistant
to ciprofloxacin, only 25% are also resistant to ceftriax-
one. Other high co-resistance rates found in E. coli were
piperacillin-tazobactam-resistant strains that are co-resistant
with TMP-SMX (77%), piperacillin-tazobactam-resistant
strains that are co-resistant with ciprofloxacin (71%), and
ceftriaxone-resistant strains that are co-resistant with
TMP-SMX (69%). To assess temporal patterns, Pearson
Chi-Square tests were performed to analyze whether co-
resistance rates remained stable or changed significantly
over time. Over time comparing the periods of 2002–2006
and 2007–2011, the rate of ceftriaxone-resistant E. coli
that are co-resistant with ciprofloxacin has been stable
around 73% (X2 = 0.005, p = 0.941) suggesting no signifi-
cant change. However, the rate of ciprofloxacin-resistant
E. coli that are co-resistant with ceftriaxone has increased
from 16% to 30% (X2 = 12.103, p < 0.001).
For K. pneumoniae (Table 2b), high co-resistance rates
were seen with ceftriaxone-resistant strains that are co-
resistant with TMP-SMX (83%), ceftriaxone-resistant
strains that are co-resistant with ciprofloxacin (60%),
and piperacillin-tazobactam-resistant strains that are
co-resistant with ceftriaxone (60%). For K. oxytoca (Table 2c),
high co-resistance was seen between ciprofloxacin-resistant
strains with ceftriaxone (60%), however it is important to
note that only 5 isolates of K. oxytoca were analyzed.
For E. cloacae (Table 2d), highest co-resistance rates were
observed with piperacillin-tazobactam-resistant strains
that are co-resistant with ceftriaxone (100%), ciprofloxacin-
resistant strains that are co-resistant with ticarcillin-
clavulanate (91%), ceftriaxone-resistant strains that are
co-resistant with ticarcillin-clavulanate (81%), and TMP-
SMX resistant strains that are co-resistant with ticarcillin-
clavulanate (80%).
In P. aeruginosa (Table 2e), high co-resistance rates were
observed with piperacillin-tazobactam-resistant strains that
are co-resistant with ceftazidime (83%), and piperacillin-
tazobactam-resistant strains that are co-resistant with
ciprofloxacin (67%). It has been previously observed that
P. aeruginosa resistant to fluoroquinolones are often
associated with resistance to other antibiotic classes
[10,12]. Interestingly, our results do not suggest a particu-
larly high co-resistance profile in ciprofloxacin-resistant
P. aeruginosa with co-resistance rates of 23-24% with
gentamicin, imipenem, ceftazidime, and piperacillin-
tazobactam.
Discussion
To our knowledge, this is one of the largest studies com-
prehensively evaluating antimicrobial co-resistance in GNB
isolated from bloodstream infections. In the first part
of our study, an unanticipated finding in our results
was that both ciprofloxacin and TMP-SMX resistance
peaked in 2006 for E. coli, and has subsequently de-
creased and stabilized.
Our experience at VGH is that there had previously
been heavy consumption of ciprofloxacin during the
time period when the resistance peaked, which suggests
this selective pressure may have contributed to this ob-
servation. We reviewed consumption data of antibiotics
at VGH based on inpatient utilization data (Figure 3),
and determined that the (DDD) of ciprofloxacin was
stable at 23,000-24,000 from 2002–2004, decreasing to
17,000 in 2005, increasing back to 23,800 in 2007, and
has since decreased to 10,100 in 2011. In comparison for
ceftriaxone utilization, the DDD has continually increased
from 3,300 to 7,200 from 2002 to 2011. The utilization
data supports that resistance rates of E. coli to ciprofloxa-
cin and ceftriaxone correlate with consumption patterns
of antibiotics during that period, which peaked in 2007
and 2011, respectively (Figure 2a). The DDD for TMP-
SMX is also of interest in that there were two consump-
tion peaks – 5,100 in 2007 and 6,700 in 2011, which again
correlates with resistance peaks in our E. coli resistance
data and provides further support that resistance pat-
terns may be associated with antimicrobial consump-
tion (Figure 2a). As most of the GNB isolates were
collected from VGH, the changes in resistance patterns
are most attributable to the antimicrobial consumption at
that site. In general, the antimicrobial consumption data
collected from VGH is representative of the usage at the
other two smaller hospitals sites.
When looking at antimicrobial resistance patterns of
E. coli in the community collected by BC Biomedical La-
boratories (45 community-based patient services centres
in Greater Vancouver, BC), we observe a significant
jump in the resistance rates of E. coli to ciprofloxacin
between 2002 and 2007 (10% to 22%) [14]. It is noted
from the BC Centre for Disease Control publication that
there was no E. coli data published for the years 2003–
2006 because antibiograms were not produced when the
resistance rates remained relatively similar, suggesting
that the jump in resistance may have occurred in 2007.
However, unlike our data after 2007, the level of resist-
ance remained relatively stable until a further increasing
trend in 2010 (26%) and 2011 (27%) [14]. One explan-
ation for this observed difference is that data from BC
Biomedical Laboratories is reflective of an outpatient-
based setting, where ciprofloxacin continues to be heav-
ily utilized for urinary tract infections. Fortunately due
to concerns regarding resistance, the 2010 Infectious
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Table 2 Summary of antimicrobial co-resistance rates determined for a) E. coli, b) K. pneumoniae, c) K. oxytoca,
d) E. cloacae, and e) P. aeruginosa
a) E. coli
No. of isolates (n) Resistance to Co-resistance rate with antibiotic (%)
2002-06 Ceftriaxone Ciprofloxacin Pip-tazo TMP-SMX Tic-clav
44 Ceftriaxone 73 14 59 59
194 Ciprofloxacin 16 8 62 31
3 Pip-tazo 33 67 67 nd
193 TMP-SMX 13 63 8 31
91 Tic-clav 29 67 nd 66
2007-11
146 Ceftriaxone 73 18 72 48
357 Ciprofloxacin 30 10 58 26
28 Pip-tazo 57 71 79 nd
373 TMP-SMX 28 56 10 27
64 Tic-clav 42 61 nd 61
2002-11
190 Ceftriaxone 73 18 69 53
551 Ciprofloxacin 25 10 60 29
31 Pip-tazo 55 71 77 nd
566 TMP-SMX 23 58 9 30
155 Tic-clav 34 65 nd 64
b) K. pneumoniae
No. of isolates (n) Resistance to Co-resistance rate with antibiotic (%)
2002-2011 Ceftriaxone Ciprofloxacin Pip-tazo TMP-SMX Tic-clav
20 Ceftriaxone 60 35 83 53
54 Ciprofloxacin 22 22 46 29
10 Pip-tazo 60 50 40 nd
44 TMP-SMX 30 57 16 37
19 Tic-clav 26 58 nd 53
c) K. oxytoca
No. of isolates (n) Resistance to Co-resistance rate with antibiotic (%)
2002-2011 Ceftriaxone Ciprofloxacin Pip-tazo TMP-SMX Tic-clav
8 Ceftriaxone 38 20 25 50
5 Ciprofloxacin 60 0 20 25
2 Pip-tazo 50 0 0 nd
5 TMP-SMX 40 20 0 100
3 Tic-clav 67 33 nd 33
d) E. cloacae
No. of isolates (n) Resistance to Co-resistance rate with antibiotic (%)
2002-2011 Ceftriaxone Ciprofloxacin Pip-tazo TMP-SMX Tic-clav
43 Ceftriaxone 26 47 37 81
17 Ciprofloxacin 65 17 59 91
9 Pip-tazo 100 11 11 nd
24 TMP-SMX 67 42 6 80
33 Tic-clav 67 30 nd 24
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Disease Society of America (IDSA) guideline for uncom-
plicated cystitis now recommends fluoroquinolone anti-
biotics as alternative agents only when other urinary tract
infection therapies cannot be used [15]. As seen by our
utilization data at VGH, in the hospital setting where pa-
tients are more ill in general, physicians are now prescrib-
ing less ciprofloxacin as empiric antimicrobial therapy
because of the high rates of resistance in both inpatient
and outpatient settings.
A further clinical utility of determining co-resistance
rates is to aid in the selection of empiric antimicrobial
coverage. For example, patients with suspected urinary
tract infection are often started on TMP-SMX while
pending culture results. However, if the patient deterio-
rates and is not responding clinically, one would have to
decide which antibiotic to use to broaden the coverage.
In the periods from 2002–2006, co-resistance of E. coli
to ceftriaxone was only 13%, so it may have been appro-
priate to switch to this antibiotic. However, co-resistance
of E. coli to ceftriaxone was 28% in 2007–2011, thus it
may be more reasonable based on our results to switch to
piperacillin-tazobactam which has a co-resistance rate of
only 10%. This is of particular importance with the ad-
vances in bacterial identification techniques, such as
Matrix Assisted Laser Desorption Ionization – Time of
Flight (MALDI-TOF) where bacterial species are identi-
fied on average 1.45 days earlier than traditional methods
[16]. The limitation of this technique is that susceptibility
testing is still required, further separating the time gap
between identification of bacteria to reporting of sus-
ceptibility results. Knowledge of local antimicrobial re-
sistance and co-resistance rates becomes more critical in
prescribing empiric antimicrobial therapy during this
period. In addition, for initial empiric therapy in critically
ill patients one may want to consider combination anti-
microbial coverage, especially in patients at high risk
for acquiring multidrug resistant organisms. With co-
resistance data, one can calculate resistant rates of
using various combinations of empiric antimicrobial treat-
ment. For example, 15% of P. aeruginosa isolates are
resistant to gentamicin (2011), and gentamicin-resistant
P. aeruginosa that are co-resistant with piperacillin-
tazobactam, imipenem and ceftazidime are 29, 33 and
11%, respectively. The resistance rates of utilizing combin-
ation gentamicin with piperacillin-tazobactam (0.15 × 0.29),
imipenem (0.15 × 0.33) or ceftazidime (0.15 × 0.11) in initial
management are 4.4, 5.0, and 1.6%, respectively. This is an
interesting finding as one may not intuitively expect the
lower resistance rates with the utilization of combination
therapy with ceftazidime versus imipenem.
A major strength of our study is that the isolates were
included from a diverse area within the Greater Vancouver
Regional District, which included the cities of Vancouver,
Richmond, and North Vancouver. The inclusion criteria
were stringent to ensure that duplicate samples from the
same patient were not included in the analysis. Our use of
only bloodstream isolates allowed us to reliably negate
effects from other possible ‘contaminant’ specimens, as
GNB isolated from blood samples are almost invariably in-
dicative of true infections. Patients with positive blood cul-
tures are generally more acutely ill and would benefit most
from the clinical utility of using co-resistance data in the
selection of an empiric antimicrobial regimen. One limita-
tion of this study is that we were unable to determine
whether these bloodstream infections were community- or
nosocomially-acquired. Due to the low number of isolates
for K. oxytoca, E. cloacae, and P. aeruginosa, the resistance
data had to be grouped into two time points, which re-
duced the ability to determine annual variations that may
have occurred. Another limitation was that we were un-
aware of whether a patient received any recent or concur-
rent antimicrobial therapies when blood cultures were
drawn, which may have yielded additional information re-
garding the incidence of failed empiric therapy. In addition,
we did not explicitly determine the source of bacteremia,
and so are unable to tell if resistance strains and patterns
Table 2 Summary of antimicrobial co-resistance rates determined for a) E. coli, b) K. pneumoniae, c) K. oxytoca,
d) E. cloacae, and e) P. aeruginosa (Continued)
e) P. aeruginosa
No. of isolates (n) Resistance to Co-resistance rate with antibiotic (%)
2002-2011 Ceftazidime Ciprofloxacin Pip-tazo Imipenem Gentamicin
11 Ceftazidime 45 50 27 9
22 Ciprofloxacin 23 24 23 23
6 Pip-tazo 83 67 33 33
13 Imipenem 23 38 18 23
9 Gentamicin 11 56 29 33
Co-resistance rates were analyzed as a summary of isolates from 2002–2011 except for E. coli, where it was possible to analyze two time periods from 2002–06
and 2007–11 due to higher isolate numbers. Co-resistance rates are rounded to the nearest percent, and those that are ≥50% are highlighted in bold font. Note:
Pip-tazo is piperacillin-tazobactam, TMP-SMX is trimethoprim-sulfamethoxazole, Tic-clav is ticarcillin-clavulanate; nd is not determined as isolates did not consistently
have both Pip-tazo and Tic-clav susceptibilities reported.
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were more commonly associated with certain types of in-
fections. Although we classified all intermediate susceptible
isolates as being resistant which would seemingly elevate
the overall resistance rates, this methodology is consistent
with clinical practice in which an antimicrobial agent with
intermediate susceptibility would generally not be used if
there were other effective alternatives. Overall, the inci-
dence of intermediate susceptible isolates was generally
low during the study period ranging from 0% to 2% for
most of the antibiotic agents.
Besides ongoing surveillance of co-resistance patterns,
one potential application for the future would be to look
at co-resistance patterns in various medical services and
ward locations. It has been proposed that unit-based anti-
biograms and combination antibiograms may be more use-
ful than national or hospital-specific antibiograms [17].
Unit-based antibiograms refers to cumulative antibiotic
susceptibility reports for patients in a particular ward over
a specified period of time, whereas combination antibio-
grams provide information on percent susceptibility to
other antibiotics if it is resistant to one particular antibiotic
[17], or essentially the co-resistance rate that we investi-
gated in this study. Unit-based combination antibiograms
can be considered for certain wards, such as the leukemia/
bone marrow transplant ward where patients can be critic-
ally ill, as this population may benefit from combination
antibiotic empiric coverage depending on local susceptibil-
ity patterns. The ability of MALDI-TOF technology to ex-
pedite identification of pathogens emphasizes the need and
importance of having accurate and up to date antimicro-
bial susceptibility data.
Conclusions
In summary, increasing antimicrobial resistance was ob-
served for several GNB over a 10-year period, and may
partially be associated with antimicrobial consumption.
The study of co-resistance rates in multidrug resistant
GNB may provide further insight into the epidemiology
of resistance acquisition. Further applications for co-
resistance data include its utility as a clinical tool to aid
in the prescription of empiric antimicrobial therapy.
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